Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Despite short-term volatility and reliance on GLP-1 momentum, HIMS remains a long-term bullish play in the consumer digital ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315 ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...